What is the Share Price of Marksans Pharma Ltd?
- Answer Field
-
The share price of Marksans Pharma Ltd for NSE is ₹ 219.39 and for BSE is ₹ 219.
BAJAJ BROKING
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
As of the latest trading session, MARKSANS PHARMA LIMITED share price is currently at ₹ 219.39, which is up by ₹ 0.06 from its previous closing. Today, the stock has fluctuated between ₹ 215.80 and ₹ 228.90. Over the past year, MARKSANS PHARMA LIMITED has achieved a return of 32.32 %. In the last month alone, the return has been -1.16 %. Read More...
Particulars | DEC 2024 (Values in Cr) |
---|---|
Revenue | 311.87 |
Operating Expense | 259.65 |
Net Profit | 55.46 |
Net Profit Margin (%) | 17.78 |
Earnings Per Share (EPS) | 1.22 |
EBITDA | 82.44 |
Effective Tax Rate (%) | 25.77 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.46 | 19.60 | 1.99 | 279.41 | 34.11 / 77.70 |
BLISS GVS PHARMA LTD | 119.00 | 15.60 | 1.24 | 1253.91 | 92.25 / 184.95 |
CIPLA LTD | 1549.65 | 25.08 | 4.41 | 125155.99 | 1310.05 / 1702.00 |
FERMENTA BIOTECH LIMITED | 260.70 | 21.60 | 2.64 | 767.27 | 145.00 / 449.00 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.46 | 21.96 | 6.19 | 279.41 | 34.11 / 77.70 |
AMRUTAJAN HEALTH LTD | 692.80 | 40.61 | 6.72 | 2002.93 | 548.05 / 861.40 |
ASTRAZENECA PHARMA IND LT | 8665.50 | 129.24 | 31.88 | 21663.75 | 5000.00 / 9199.00 |
BLISS GVS PHARMA LTD | 119.00 | 15.45 | 1.22 | 1253.91 | 92.25 / 184.95 |
Particulars | Sep 2024 (₹ in Cr) | Jun 2024 (₹ in Cr) | Mar 2024 (₹ in Cr) | Dec 2023 (₹ in Cr) | Sep 2023 (₹ in Cr) |
Revenue | 308.63 | 254.53 | 225.20 | 241.36 | 204.67 |
Operating Expense | 263.65 | 220.38 | 198.98 | 208.09 | 176.10 |
Net Profit | 63.20 | 32.02 | 32.99 | 25.29 | 31.29 |
Net Profit Margin (%) | 20.47 | 12.58 | 14.64 | 10.47 | 15.28 |
Earnings Per Share (₹) | 1.39 | 0.71 | 0.73 | 0.56 | 0.69 |
EBITDA | 83.64 | 49.42 | 46.09 | 43.30 | 53.23 |
Effective Tax Rate (%) | 17.19 | 24.30 | 14.08 | 26.90 | 29.68 |
Key Highlights:
Particulars | Mar 2024 (₹ in Cr) | Mar 2023 (₹ in Cr) |
Revenue | 853.27 | 732.00 |
Operating Expense | 743.46 | 650.23 |
Net Profit | 133.76 | 112.65 |
Net Profit Margin (%) | 15.67 | 15.39 |
Earnings Per Share (₹) | 2.95 | 2.50 |
EBITDA | 202.01 | 180.52 |
Effective Tax Rate (%) | 22.18 | 20.50 |
Key Highlights:
Particulars | Ex-Date | Record Date |
Dividend per Share (₹) | 07 Jun, 2023 | 07 Jun, 2023 |
Dividend Yield (%) | 0.5 | Equity Shares |
Key Highlights:
Who is the CEO of Marksans Pharma Ltd?
Marksans Pharma Ltd is led by Mr. Mark Saldanha, who serves as the Managing Director and Chief Executive Officer of the company. Under his leadership, the company has expanded its presence in the global pharmaceutical market and achieved significant growth in various regions. Mr. Saldanha’s vision has been instrumental in driving the company’s strategic acquisitions, as well as in its research and development initiatives.
When was Marksans Pharma established?
Marksans Pharma Ltd was initially incorporated as Tasc Pharmaceuticals Limited in April 1982. Following a Scheme of Amalgamation, the company’s name was changed to Marksans Pharma Ltd on 10th October 2005. The rebranding marked the beginning of the company’s expanded focus on pharmaceutical formulations, and since then, it has become a prominent player in the pharmaceutical sector.
What factors influence the Marksans Pharma Share Price?
The Marksans Pharma share price is influenced by several key factors, including:
Is Marksans Pharma debt-free?
Marksans Pharma Ltd is not entirely debt-free. However, the company has maintained a manageable level of debt as part of its capital structure. It strategically acquires businesses and invests in research and development to fuel its growth. The debt levels are often monitored to ensure they do not adversely impact the company's financial health. Despite this, the company has successfully maintained profitability and strong cash flow, helping it manage its liabilities efficiently.
What is the CAGR of Marksans Pharma Share?
The Marksans Pharma share price has demonstrated a Compound Annual Growth Rate (CAGR) of:
This impressive growth rate highlights the company’s consistent performance and the market’s positive response to its strategic initiatives, including acquisitions and expanding its product portfolio.
How has the Marksans Pharma Share Price performed over the past year?
Over the past year, the Marksans Pharma share price has seen a remarkable increase of 96%. This surge in share price reflects strong financial performance, successful product approvals, and the company's continued expansion in both domestic and international markets. The robust growth in the past year has also been fueled by investor confidence, supported by strategic acquisitions such as Tevapharm India and the company's increasing presence in the global pharmaceutical industry.
Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982. Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005. The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation. The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai.
In 2004-05, the Company amalgamated with M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited) pursuant to High Court order dated 19th August, 2005. As provided in the approved Scheme of Amalgamation, necessary shares were issued to the shareholders of the M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited).
The Company acquired majority stake in Nova Pharmaceuticals Australasia Private Limited in 2005; further, it acquired two companies, Bell Sons & Company (Druggists) Limited and Relonchem Limited in the UK in 2008. The Company received first ANDA approval in the USA in 2011. It acquired Time-Cap Laboratories Inc. in the US in 2015.
The Company launched the CNS-Cerebella division in FY 2017-18. It launched soft gelatin capsules, a niche category, Launched two products and received CRL for 4 ANDAs for approval with the USFDA.
The Company commissioned a new R&D center at Navi Mumbai, apart from one in Goa in 2019-20.
The Company acquired the business of Tevapharm India Private Limited relating to the manufacture and supply of pharmaceutical formulations in Verna, Goa as a going concern on a slump sale in April, 2023.
The share price of Marksans Pharma Ltd for NSE is ₹ 219.39 and for BSE is ₹ 219.
The market cap of Marksans Pharma Ltd for NSE is ₹ 99,41.96 Cr. and for BSE is ₹ 99,24.28 Cr. as of now.
The 52 Week High and Low of Marksans Pharma Ltd for NSE is ₹ 358.70 and ₹ 130.00 and for BSE is ₹ 358.50 and ₹ 130.15.
You can trade in Marksans Pharma Ltd shares with Bajaj Broking by opening a Demat Account.
The 1 year returns on the stock has been 32.32%.
Marksans Pharma Ltd share price is for NSE ₹ 219.39 & for BSE ₹ 219 as on Apr 30 2025 03:30 PM.
The market cap of Marksans Pharma Ltd for NSE ₹ 99,41.96 & for BSE ₹ 99,24.28 as on Apr 30 2025 03:30 PM.
As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Marksans Pharma Ltd share is 54.07.
As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Marksans Pharma Ltd share is 28.48.
You can trade in Marksans Pharma Ltd shares with Bajaj Broking by opening a demat account.
To buy Marksans Pharma Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Marksans Pharma Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found